AHSG modulators(alpha 2-HS glycoprotein modulators), TRPC3 antagonists(Short transient receptor potential channel 3 antagonists), TRPC6 antagonists(transient receptor potential cation channel subfamily C member 6 antagonists)

Therapeutic Areas

NeoplasmsNervous System DiseasesCardiovascular Diseases+ [7]

Active Indication

Chronic Kidney DiseasesVision DisordersNon-Small Cell Lung Cancer+ [7]

Inactive Indication

Acute Chest SyndromeAttention Deficit DisorderHemoglobin SC Disease+ [1]

Originator Organization

DSM Biomedical, Inc.

Active Organization

University of Nevada

Texas A&M University

Seoul National University

+ [5]

Inactive Organization

Micelle BioPharma, Inc.

DSM NUTRITIONAL PRODUCTS LLC

Sancilio & Co., Inc.

License Organization

Pentec Health, Inc.

Drug Highest PhasePreclinical

First Approval Date-

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC22H32O2

InChIKeyMBMBGCFOFBJSGT-KUBAVDMBSA-N

CAS Registry6217-54-5

388

Clinical Trials associated with Docosahexaenoic acid

ChiCTR2500110254

/ Not yet recruitingPhase 4IIT

Omega-3/Omega-6 Imbalance and Post-Weight-Loss Regain in Obese Patients: Association and Intervention

Start Date26 Oct 2025

Sponsor / Collaborator

Affiliated Hospital of Guangdong Medical University

[+1]

ChiCTR2500110506

/ Not yet recruitingNot ApplicableIIT

N-3 Polyunsaturated Fatty Acid Supplementation for Muscle Health in Community-Dwelling Older Adults at High Risk of Sarcopenia: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial

Start Date01 Sep 2025

Sponsor / Collaborator

National Natural Science Foundation of China

NCT06494488

/ RecruitingEarly Phase 1IIT

Differential Thrombogenesis Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Mediated by High-Density Lipoprotein (HDL)

The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels.
The purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Participants will:
Visit the clinic 3 times during study checkups, tests and blood collection. Randomized to either the EPA or the DHA supplementation group. Be given a 28-day food and activity log.

Start Date10 Jul 2025

Sponsor / Collaborator

The Miriam Hospital

[+2]

100 Clinical Results associated with Docosahexaenoic acid

100 Translational Medicine associated with Docosahexaenoic acid

100 Patents (Medical) associated with Docosahexaenoic acid

46,967

Literatures (Medical) associated with Docosahexaenoic acid

01 Feb 2026·Intensive and Critical Care Nursing

Effects of omega-3 fatty acids on hyper-inflammatory response and clinical outcomes in critically ill patients: a meta-analysis

Review

Author: Liu, Ting ; Wang, Hai-Fang ; Wang, Xiao-Hua ; Wang, Xin ; Wang, Can ; Cai, Jian-Zheng

BACKGROUND:

There are still debates regarding the impact of omega-3 fatty acids on immune response and clinical outcomes in critically ill patients.

OBJECTIVE:

Explore the effects of omega-3 fatty acids on hyper-inflammatory response and clinical outcomes in critically ill patients.

METHODS:

We searched five databases from inception to July 18, 2024 and collected randomized controlled trials in which critically ill patients treated in an intensive care unit (ICU) were administered omega-3 fatty acids as a supplement. Data were expressed as mean difference, standard mean difference, or odds ratio with 95% confidence interval (CI).

RESULTS:

There were 41 randomized controlled trials that met the inclusion criteria, and they involved 3152 patients. The intervention with omega-3 fatty acids significantly reduced the following biomarkers: white blood cell count on day 3 and day 6/7, tumor necrosis factor-α (TNF-α) on day 3 and day 5, interleukin-1 (IL-1), interleukin-6 (IL-6), and procalcitonin at the last observation post-intervention. The intervention also reduced the Sequential Organ Failure Assessment (SOFA) score on day 5 and lowered the risk of secondary infections and new sepsis/septic shock, both determined during follow-up. It also significantly shortened the ICU stay and reduced the 28-day mortality rate, although ICU mortality rate remained unchanged.

CONCLUSIONS:

Omega-3 fatty acids supplementation may be effective in modulating hyper-inflammatory responses, reducing the risk of complications and disease severity, and improving clinical outcomes.

IMPLICATIONS FOR CLINICAL PRACTICE:

Omega-3 fatty acids may serve as a potential nutritional therapy for critically ill patients, when medical staff identify the hyperinflammatory status of patients based on medical history, clinical manifestations, and laboratory results.

01 Jan 2026·MARINE POLLUTION BULLETIN

Potentially toxic element hazards and fatty-acids profile of fish species from Agulu Lake of Southeast Nigeria

Article

Author: Offor, Chideraa Courage ; Okafor, Chioma Perpetua ; Nduka, John Kanayochukwu

Omega-3 fatty acids in fish promote therapeutic effects and heart health in humans when regularly consumed, hence the need for fish and water pollution status assessments of Agulu Lake, Eastern Nigeria. Eight fish species were collected during dry and rainy seasons. 3 fish anatomical sites (muscles, brain and liver) were analysed for Pb, Cd, Cu, Co, Mn, Fe, Cr, and Ni using atomic absorption spectrometry, and fatty acid profile using gas chromatography technique. Maximum concentration of Cd (1.321 mg/kg) in O. niloticus, was above WHO limit (0.5 mg/kg). Mean PTEs concentration of fish tissues followed decreasing order: Cd > Cr > Co > Mn > Fe > Ni > Pb > Cu (dry season); Cr > Fe > Cd > Co > Pb > Cu = Ni > Mn (rainy season). The ∑n-3PUFA (% dry weight) in fish tissues ranged from 42.22 (O. niloticus) to 349.63 (X. nigri), with docosahexaenoic acid as main contributor in the muscles of X. nigri. Fat contents of all the fish species in dry season were higher than rainy season values, except X. nigri. Risk metal assessment of P.mariae, N. notopterus, and C.zilli had its muscles, brain and liver exceeding cancer risk permissible limit for Cd and Cr for all age groups, indicating potential health hazards for exposed subjects. The total PTEs intake is 1.76 mg/kg per week or 91.81 mg/kg per year in rainy season, hence, strict regulatory control is recommended to ensure food safety.

01 Jan 2026·JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Dietary omega-3 alleviates copper-induced nephrotoxicity via suppression of NLRP3-mediated pyroptosis and lipid metabolism disorder in chickens

Article

Author: Wang, Ruoqi ; Zhang, Yixin ; Lu, Hongmin ; Xing, Mingwei ; Liu, Manhong ; Wang, Qi ; Zhang, Xin ; Zhen, Hongyue ; Zhang, Yue

Excessive use of copper (Cu) in poultry farming induces nephrotoxicity closely related to inflammatory response and lipid metabolism disorder, but the mechanism remains unclear. Omega-3 (Ω-3), a natural polyunsaturated fatty acid with anti-inflammatory and antioxidative stress properties, has been demonstrated to exert protective effects on the kidneys. However, whether Ω-3 can alleviate Cu-induced renal injury and the underlying mechanisms remain unclear. Therefore, we investigated the effects of Cu exposure on chicken kidney tissues and CEK cells in this study. Subsequent dietary supplementation with Ω-3 was administered to evaluate its ameliorative effects on Cu-induced renal injury. Cu exposure significantly disrupted mitochondrial homeostasis. This was evidenced by downregulated mRNA levels of OPA1 and MFN1/2, reduced ATP content, tricarboxylic acid (TCA) cycle dysfunction, mitochondrial membrane depolarization, and excessive ROS accumulation. Electron microscopy confirmed that Cu exposure induced pyroptosis in renal cells, accompanied by activation of the NF-κB-NLRP3-GSDMD pathway, leading to significantly upregulated expression of IL-1β, IL-18, Caspase-1, ASC, and GSDMD. Additionally, Cu exposure disrupted lipid metabolism by upregulating PPARγ, SREBP1, and Fas while downregulating PGC-1α, as evidenced by abnormal lipid droplet accumulation observed under electron microscopy. Furthermore, Cu exposure significantly inhibited the Wnt3a/β-catenin signaling pathway, impairing renal repair functions. Notably, the administration of Ω-3 effectively alleviated these adverse effects. This study reveals that Ω-3 exerts its protective effects against Cu-induced nephrotoxicity by modulating the NF-κB-NLRP3-GSDMD axis, the Wnt/β-catenin signaling pathway, and lipid metabolism for the first time. This provides a dietary strategy to enhance poultry health in intensive farming.

News (Medical) associated with Docosahexaenoic acid

29 Oct 2025

·www.sciencedaily.com

Omega-3 benefits may vanish quickly after you stop

Finnish scientists found that eicosapentaenoic acid (EPA) from fish oil impacts each person’s metabolism uniquely. Participants showed strong but short-lived increases in EPA levels, with significant differences in lipid pro The results reveal how metabolism shapes individual responses to omega-3 supplements and underscore the need for personalized heart health strategies. A new study has found that the benefits of a fatty acid known as eicosapentaenoic acid vary widely from person to person. Researchers say the results highlight how individual metabolism plays a crucial role in protecting against cardiovascular disease. Scientists in Finland explored how eicosapentaenoic acid (EPA), an omega-3 fatty acid found in fish oil, affects metabolism and blood lipid levels in healthy adults. While EPA is already recognized for lowering cardiovascular risk in people with high cholesterol or heart disease, its effects in otherwise healthy individuals have not been well understood. Little was also known about how EPA becomes incorporated into lipoproteins, the particles that transport fat molecules through the bloodstream. High-Dose Supplement Study Reveals Wide Variation In this research, 38 volunteers were given unusually high doses of EPA supplements. Blood samples were collected before, during, and after supplementation to observe how the body processed the fatty acid. The results showed large differences among participants in how their bodies responded to EPA. "The samples taken during supplementation clearly show the effect of EPA on all participants. Having said that, all samples were different among the group. In other words, each individual has a unique lipoprotein lipidome in their circulation, a 'lipid fingerprint', if you will, that persisted despite EPA supplementation," explains Professor Katariina Öörni, one of the lead authors from the Faculty of Biological and Environmental Sciences, University of Helsinki, and the Wihuri Research Institute. The researchers confirmed that EPA is absorbed efficiently, causing a sharp rise in its concentration in the blood. However, the levels declined quickly once supplementation stopped. The strongest changes were observed in participants who started with lower baseline EPA levels. In addition, EPA improved blood lipid profiles and reduced the tendency of lipoproteins to attach to the walls of arteries -- an important factor in preventing atherosclerosis. Short-Term Effects and Future Research Because the study lasted only a short time, it did not measure long-term outcomes. Still, the findings reveal that EPA can alter blood lipid composition and influence early risk mechanisms for atherosclerosis even in healthy people. "The findings highlight the importance of metabolism in the prevention of cardiovascular diseases. EPA's effects varied more between individuals than we expected. We also demonstrated that these effects dissipate quickly, which is good to know in case EPA were to have adverse effects," notes Doctoral Researcher Lauri Äikäs. Next, the team plans to study how EPA supplementation affects inflammatory cells and the production of lipid mediators that help control inflammation. "It's interesting to see how, for instance, dietary changes affect lipoprotein quality, or the individual lipid fingerprint," Öörni adds.

Clinical Result

17 Sep 2025

·www.einpresswire.com

LogsDay Reports: Millions Ignore Dry Eyes Treatment โ Until Itโs Too Late

Millions ignore dry eyes, risking vision damage. LogsDay explains causes, symptoms, treatments, and when to see a doctor. Many see dry eye as normal aging, but early treatment can prevent lasting vision damage.” — Dr. Piotr Woลบniak, dry eye specialist PUNE, MAHARASHTRA, INDIA, September 17, 2025 / EINPresswire.com / -- ๐๐จ๐ ๐ฌ๐๐๐ฒ , a leading lifestyle and wellness news publisher, issued a health alert revealing that millions of people worldwide are choosing to ignore dry eyes symptoms. What many dismiss as mild discomfort may result in serious risks if not treated early. The article โ ๐๐ก๐ฒ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง๐ฌ ๐๐ ๐ง๐จ๐ซ๐ ๐๐ซ๐ฒ ๐๐ฒ๐๐ฌ โ ๐๐ง๐ญ๐ข๐ฅ ๐๐ญโ๐ฌ ๐๐จ๐จ ๐๐๐ญ๐โ outlines what causes dry eye syndrome, the progression of untreated dry eyes, the best dry eyes treatment options, and when to consult a medical professional. ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ โข Common triggers for dry eyes include prolonged screen use, aging (particularly after 50), hormonal changes (notably during menopause), exposure to dry climates or wind, medical conditions such as diabetes or autoimmune disorders, contact lens wear, and certain medications. โข Early symptoms are mild: itching, burning, gritty sensation, slight blurriness. When neglected, they can lead to serious issues such as corneal damage, inflammation, ulcers, and vision impairment. โข Available dry eyes treatment options range from over-the-counter artificial tears and lifestyle adjustments (screen breaks, humidity control) to nutritional support (omega-3 fatty acids, hydration), and medical treatments including prescription drops, in-office procedures, and punctal plugs. โข It is important to see an eye doctor if symptoms persist beyond two weeks, if pain or light sensitivity develops, or if daily activities like reading, driving, or screen work become difficult. ๐๐ฑ๐ฉ๐๐ซ๐ญ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ โ๐ด๐๐๐ ๐๐๐ ๐๐๐ ๐๐๐ ๐๐ ๐ ๐๐๐๐๐๐ ๐๐๐๐ ๐๐ ๐๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐๐๐ ๐๐ ๐๐๐๐๐๐,โ says Dr. Piotr Woลบniak, a refractive surgeon and dry eye specialist. โ๐จ ๐๐๐๐๐๐ ๐๐๐ ๐๐๐๐ ๐๐๐๐๐ ๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐ โ ๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐ ๐๐๐๐โ๐ ๐๐๐๐ ๐๐๐๐๐๐ ๐๐๐ ๐๐๐๐.โ โ๐๐ฎ๐ฟ๐น๐ ๐ฑ๐ฒ๐๐ฒ๐ฐ๐๐ถ๐ผ๐ป ๐ฎ๐ป๐ฑ ๐๐ฟ๐ฒ๐ฎ๐๐บ๐ฒ๐ป๐ ๐ผ๐ณ ๐ฑ๐ฟ๐ ๐ฒ๐๐ฒ๐ ๐ฎ๐ฟ๐ฒ ๐ป๐ผ๐ ๐ท๐๐๐ ๐ฎ๐ฏ๐ผ๐๐ ๐ฐ๐ผ๐บ๐ณ๐ผ๐ฟ๐ โ ๐ฝ๐ฟ๐ผ๐๐ฒ๐ฐ๐๐ถ๐ป๐ด ๐๐ผ๐๐ฟ ๐๐ถ๐๐ถ๐ผ๐ป ๐บ๐ฒ๐ฎ๐ป๐ ๐ฎ๐๐ผ๐ถ๐ฑ๐ถ๐ป๐ด ๐น๐ผ๐ป๐ด-๐๐ฒ๐ฟ๐บ ๐ฑ๐ฎ๐บ๐ฎ๐ด๐ฒ ๐ฎ๐ป๐ฑ ๐ฝ๐ผ๐๐ฒ๐ป๐๐ถ๐ฎ๐น๐น๐ ๐๐ถ๐๐ถ๐ผ๐ป ๐น๐ผ๐๐.โ โ Dr. Aisha Kumar, ophthalmologist with over 15 yearsโ experience, Mumbai Eye Institute. ๐๐ก๐ฒ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐๐ญ๐๐ง ๐๐๐ญ๐ฌ ๐๐๐ฅ๐๐ฒ๐๐ Many delay care because they believe dry eyes are just a natural part of aging, or assume over-the-counter drops will solve the issue. Others might be more focused on trending health topics, overlooking the risks of untreated dry eyes. Studies show that while over half of adults in the US and Europe report symptoms, only about 17-20% obtain formal diagnosis. Delay makes treatment more difficult, more expensive, and damage harder to reverse. ๐๐ก๐๐ญ ๐๐จ๐ฎ ๐๐๐ง ๐๐จ ๐๐จ๐ฐ: ๐๐ซ๐๐ฏ๐๐ง๐ญ๐ข๐ฏ๐ ๐๐๐๐ฌ๐ฎ๐ซ๐๐ฌ & ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐ฉ๐ญ๐ข๐จ๐ง๐ฌ 1. Monitor symptoms: Itching, burning, feeling of something in the eye, blurry vision. If they last more than a couple of weeks or worsen, consult an eye care professional. 2. Lifestyle changes: Follow the 20-20-20 rule (every 20 minutes, look 20 feet away for 20 seconds), protect eyes from wind, use humidifiers, reduce screen glare. 3. Lubrication: Use artificial tears or lubricating eye drops for mild to moderate dry eyes. 4. Nutrition & hydration: Include omega-3 fatty acids (e.g. in salmon, flax seeds), stay well hydrated, reduce alcohol and caffeine which may dehydrate. 5. Medical treatments when needed: Prescriptions for inflammation, in-office procedures, or use of punctal plugs if tear drainage needs correction. ๐๐ก๐๐ง ๐ญ๐จ ๐๐๐ ๐ ๐๐จ๐๐ญ๐จ๐ซ It is time to consult a specialist if: โข Symptoms last more than two weeks despite home care. โข Pain, redness, light sensitivity, or changes in vision occur. โข Daily life tasks like reading, driving at night, or using screens become difficult. ๐๐๐จ๐ฎ๐ญ ๐๐จ๐ ๐ฌ๐๐๐ฒ LogsDay is a digital platform dedicated to wellness, lifestyle, and trending news. It delivers practical insights, expert-backed health content, and actionable tips to help readers protect their well-being. ๐๐๐ฅ๐๐ญ๐๐ ๐๐จ๐ฉ๐ข๐๐ฌ For readers interested in understanding the broader landscape of health anxieties, including why people often postpone medical attention, read more about ๐๐๐๐ซ ๐จ๐ ๐ญ๐ก๐ ๐๐๐ง๐ญ๐ข๐ฌ๐ญ ๐๐ง๐ ๐จ๐ญ๐ก๐๐ซ ๐๐๐ซ๐-๐๐ฏ๐จ๐ข๐๐๐ง๐๐ ๐๐๐ก๐๐ฏ๐ข๐จ๐ซ๐ฌ here. KOYEL GHOSH Founder & Researcher, LogsDay koyel@logsday.com Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

16 Aug 2024

·www.businesswire.com

Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.

VANCOUVER, British Columbia--( BUSINESS WIRE )-- Lobe Sciences, Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) , a biopharmaceutical company focused on developing products to treat diseases with unmet medical needs, today announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma, Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate. Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera. Dr. Sancilio, Chairman and CEO of Lobe Sciences said, “At present, Lobe Sciences has a complex corporate structure. By establishing Alera Pharma, we are simplifying the operations of the Company into just three entities. Lobe Sciences, Ltd will provide common services to the two operating subsidiaries - Alera and Altemia, LLC. The creation of two separate operating companies will allow each entity to create value within their respective therapeutic areas; neurology and hematology.” The Company also announces the receipt from the US PTO of a Notice of Allowance for its U.S. Patent Application Serial No. 18/411,576. About Lobe Sciences Ltd. Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia ® , a medical food designed to meet the needs of sickle cell patients globally. Cautionary Statement Regarding "Forward-Looking" Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the composition of the management team of Alera and the ownership of Lobe Sciences Australia Pty Ltd., are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the management team of Alera will be appointed as currently expected and that Lobe Sciences Australia Pty Ltd. will become a subsidiary of Alera as currently anticipated. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the management team of Alera will be appointed differently as currently expected and that Lobe Sciences Australia Pty Ltd. will not become a subsidiary of Alera as currently anticipated. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Executive ChangePhase 1Phase 2

100 Deals associated with Docosahexaenoic acid

External Link

KEGG	Wiki	ATC	Drug Bank
-	Docosahexaenoic acid	V06D	DB03756

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemoglobin SC Disease	Phase 3	-	Micelle BioPharma, Inc.	01 Mar 2019
Hypertriglyceridemia	Phase 3	-	Sancilio & Co., Inc.	28 Nov 2013
Attention Deficit Disorder	Phase 3	United States	DSM NUTRITIONAL PRODUCTS LLC	01 Sep 2013
Acute Chest Syndrome	Phase 2	United States	Micelle BioPharma, Inc.	02 Mar 2017
Chronic Kidney Diseases	Preclinical	Japan	Hiroshima University	13 Jun 2019
Vision Disorders	Preclinical	United States	Case Western Reserve University	07 May 2017
Non-Small Cell Lung Cancer	Preclinical	South Korea	Chungnam National University	15 Jul 2016
Coronary Disease	Preclinical	United States	Veterans Administration Medical Center	30 Oct 2012
Colorectal Cancer	Preclinical	United States	Texas A&M University	15 Apr 2010
Obesity	Preclinical	United States	The University of Texas at Austin	15 Apr 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03757585 (CTgov)	Phase 4	Learning Disabilities \| Autism Spectrum Disorder \| Autistic Disorder	54	Open-label Treatment with N-acetylcysteine (N-Acetylcysteine)	adgsbosvmz(vrariugxxe) = gxqptzbjce ihsosfsgkj (zpvwgzlpvs, 8.1) View more	-	05 Jun 2025
				Omega-3 Fatty Acids+Inositol (Omega-3 Fatty Acids + Inositol)	ksebwlfyfh(zczojubfhi) = byoszhzjga kgjqwkmnyx (dqgqtztihi, 7.7) View more
NCT03120299 (Pubmed \| Med)	Phase 4	Diabetes Mellitus, Type 2	309	omega-3 fatty acids (Fish oil (FO))	sodapipmao(rywxxqclbw) = zmbfrapbok qpffopxfue (iztptlceyf, -2.01 to -1.01)	Positive	01 Jan 2025
				omega-3 fatty acids (Corn oil)	sodapipmao(rywxxqclbw) = fvscklymgz qpffopxfue (iztptlceyf, -1.15 to -0.16)
NCT01814527 (CTgov)	Not Applicable	Brain Concussion	62	Docosahexaenoic acid (Docosahexaenoic Acid)	zbvvxosuwg(wxhltutmeo) = erzbpnwnfr jvrffvsdsz (nvzqvfigzr, akwnqortvf - xpnabmofgr) View more	-	24 Apr 2024
				Placebo (Placebo)	zbvvxosuwg(wxhltutmeo) = tdaarxapqv jvrffvsdsz (nvzqvfigzr, fzivlrlucp - oixevpmacq) View more
NCT03965988 (Pubmed \| Pediatr Neurol)	Phase 3	Syncope	-	Docosahexaenoic Acid (DHA) plus Piracetam	nodgjrdlfl(srvpynjzdv) = ataplrqors uigiogqxpf (vygijnczvk )	Positive	01 Nov 2023
				Piracetam plus Placebo	nodgjrdlfl(srvpynjzdv) = womxvwlkuw uigiogqxpf (vygijnczvk )
NCT03750968 (L-ZIP, CTgov)	Phase 2	Malnutrition	47	Carotenoid Group (Carotenoid Group)	lwbkqskltw(offronupvo) = jiboyyizmm aknsvuvttm (npxucgylfi, 688) View more	-	11 Jul 2023
				Control Group (Control Group)	lwbkqskltw(offronupvo) = ffqzxvyydv aknsvuvttm (npxucgylfi, 470) View more
NCT01883817 (CTgov)	Phase 3	Attention Deficit Disorder	30	Placebo (Placebo)	lpvmdftapi(oiaujllujh) = krqrxtzoak jmpmymntkj (wlrvruzjkw, 8.5) View more	-	16 Mar 2022
				DHA Omega-3 (DHA Omega-3)	lpvmdftapi(oiaujllujh) = qpejraezru jmpmymntkj (wlrvruzjkw, 6.6) View more
NCT01849250 (CTgov)	Phase 2	Triple Negative Breast Cancer \| Fibrocystic Breast Disease \| Invasive Mammary Carcinoma ... View more	65	Placebo (Placebo)	wjgyrftvfa(nhujzxeljb) = rypwgwkprm nipvbwycan (bgqnstqmta, 0.93) View more	-	28 Dec 2021
				Docosahexaenoic Acid (Docosahexaenoic Acid)	wjgyrftvfa(nhujzxeljb) = miqpuyqlsh nipvbwycan (bgqnstqmta, 0.78) View more
NCT03700957 (Pubmed \| Saudi Pharm J)	Not Applicable	Enterocolitis, Necrotizing	67	DHA group	szzrzlzyfy(edymvxrdqj) = xcawtvejof wpatkyxcwl (mofbmikjun )	-	01 Nov 2021
				Docosahexaenoic acid (Control group)	szzrzlzyfy(edymvxrdqj) = rmcrgnhofd wpatkyxcwl (mofbmikjun )
NCT02626299 (Pubmed)	Phase 3	Pregnancy \| Obstetric Labor, Premature	1,100	1000 mg DHA	vgasvpdqjb(lpjmhjaadw) = enysaiepuv kzkghtenug (yhtcqwaosl )	Positive	01 Jun 2021
				200 mg DHA	vgasvpdqjb(lpjmhjaadw) = tpeuzjjdqi kzkghtenug (yhtcqwaosl )
NCT01502813 (CTgov)	Not Applicable	Cognition	40	Omega-3 Fatty Acids+Creatine+Citicoline	bjoxbvkdoi(zxaldkmsdk) = zaizitcykg brjfivibhs (jydtbqfwbj, rkpdmauplp - lofchevcjp) View more	-	22 Apr 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis